CEO Padraig McDonnell contends that Biovectra’s capabilities are in the “sweet spot” of GLP-1s and complex chemistries, with strong medium and long-term growth potential.
The agreement initiates a technology transfer process to Minaris’ GMP facility in Allendale, New Jersey, supporting BrainStorm’s readiness for trial execution.